BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Signet Laboratories, Inc. Announces The Release Of An sAPPbeta Antibody Critical For Alzheimer's Disease Research


4/26/2006 10:27:43 AM

DEDHAM, Mass., April 26 /PRNewswire/ -- Signet Laboratories, Inc., a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, today announced the availability of a polyclonal antibody specific for sAPPbeta, a cleavage product of amyloid precursor protein.

Alzheimer's disease (AD) presently affects over 4 million people, a number that is expected to quadruple over the next 15 years. There is no known cure and diagnosis can only be confirmed post mortem. AD is characterized pathologically by the formation of extracellular amyloid plaques in the brains of patients. These plaques are predominantly composed of beta amyloid protein, which is derived from the proteolytic processing of amyloid precursor protein.

"Quantitative analysis of the cleavage products generated during the processing of amyloid precursor protein is critical to the understanding of the pathogenesis of Alzheimer's disease," said Joe Bertelsen, Neuroscience Product Manager, Signet Laboratories, Inc. "Signet's sAPPbeta specific antibody, the first of its kind commercially available to AD researchers, will serve as a powerful tool in the development of diagnostic and therapeutic strategies for this devastating disease."

About Signet Laboratories, Inc.

Signet Laboratories, Inc. (Dedham, MA) is a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease. Signet was created in 1989 as a commercial spinout of Johnson & Johnson's Cambridge Research Laboratories, Inc.

The Company was founded to continue the mission originally established at CRL -- the early detection and recurrence monitoring of patients with cancer and infectious disease. Signet has developed patented technology for diagnosis and recurrence monitoring and for risk assessment of asymptomatic patients in these areas. For more than a decade, the Company has aggressively maintained licensing and development programs, which are responsible for its broad patent and intellectual property estate.

Contact Information Signet Company Contact Neuroscience Contact Colleen Scott Joseph Bertelsen Signet Laboratories, Inc. Signet Laboratories, Inc. 180 Rustcraft Road 180 Rustcraft Road Dedham, MA 02026 Dedham, MA 02026 Phone: 781.915.1404 Phone: 781.915.1402 Fax: 781.461.2456 Fax: 781.461.2456 http://www.signetlabs.comcscott@signetlabs.com

Signet Laboratories, Inc.

CONTACT: Colleen Scott, +1-781-915-1404, cscott@signetlabs.com; or JosephBertelsen, +1-781-915-1402, both of Signet Laboratories, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->